Dong — A Socio Holdings Subsidiary Wins KRW 13.5 Billion Drug Manufacturing Contract

Dong-A Socio Holdings' subsidiary signed a KRW 13.5 billion pharmaceutical contract manufacturing agreement with a global drugmaker. The contract represents 13% of the subsidiary's 2025 standalone revenue. Signed Oct. 16, 2026, the contract runs through June 30, 2027. * The agreement includes a KRW 1.88 billion advance payment, with installment payments tied to completion of client-requested tasks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A Socio Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261016800364), on October 16, 2026, and is solely responsible for the information contained therein. (C)